Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer

Summary

To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate alone in patients with early endometrial cancer.

Timeline

Start

2017-07-04

Primary completion

2020-06-18

Completion

2020-06-18

Outcome

Missed primary endpoint

paper No significant difference in 16-week CR rate were found between MA and MA + LNG-IUS groups (19.2% vs. 25.0%, p=0.610; PMID 36562136 ↗

Publications

• Xu Z, Yang B, Guan J, Shan W, Liao J, Shao W, Chen X. Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). J Gynecol Oncol. 2023 Jan;34(1):e32. doi: 10.3802/jgo.2023.34.e32. Epub 2022 Dec 15.

Drugs

Indications